Les Tillack

Biography

Working for Progen Pharmaceuticals for 11 years prior to becoming CEO of LuinaBio (previously PharmaSynth) in 2009. During his time at Progen, Les has worked with and overseen Progen’s anti-cancer drug PI-88s progression from preclinical to phase 3 manufacture. He has also been responsible for the tech transfer and manufacture of many client products for both clinical applications and marketed products. Les holds a Bachelor of Science in microbiology and a Bachelor of Engineering in Chemical Engineering. Prior to commencing with Progen, Les spent 11 years working in clinical pathology for Drs Sullivan and Nicolaides Pathologists and has worked on various research projects for both the Department of Primary Industries and the University of Queensland.

Research Interest

  Pharmaceutics & Biopharmaceutics Drug Targeting & Drug Development Pharmaceutical Research Pharmaceutical Materials Pharmaceutical Formulations Pharmaceutical Biotechnology Pharmaceutical Nanotechnology Pharmaceutical Technology Pharmaceutical Manufacturing Pharmaceutical Engineering Drug Delivery Technologies Medical Devices Drug Regulatory Affairs Pharmaceutical Management